How do Tresiba and Basaglar compare side by side?
From the US Tresiba and Basaglar labels. Low blood sugar numbers come from different trials with different definitions. The four rows above are the short version.
Show all 9 rowsHide table
| Tresiba | Basaglar | |
|---|---|---|
| Insulin | Insulin degludec1 | Insulin glargine 100 units/mL2 |
| Approved for | People 1 year and older with diabetes1 | Adults and children with type 1 diabetes; adults with type 22 |
| When injected | Adults: once daily at any time of day; children: same time every day1 | Once daily at the same time every day2 |
| Type 2 start, new to insulin | 10 units once daily1 | 0.2 units/kg or up to 10 units once daily2 |
| Switching from another basal insulin | Adults: same unit dose; children: 80%1 | From glargine 100 units/mL: same dose; from glargine 300 units/mL or twice-daily NPH: 80%2 |
| Pens | U-100 FlexTouch up to 80 units; U-200 FlexTouch up to 160 units; also a U-100 vial1 | U-100 KwikPen or Tempo Pen, up to 80 units2 |
| Opened pen lasts | 56 days1 | 28 days2 |
| Missed dose | Adults: inject when found, at least 8 hours from the next; children: call the provider1 | No rule in the label2 |
| Boxed warning | None1 | None2 |
Reviewed . Half-life figures are shown only where the value Dose Track uses agrees with the cited source.
What did each label compare?
In Tresiba's 52-week type 1 trial against insulin glargine U-100, the HbA1c difference was −0.01% and met the set margin of 0.4%. The label says adults on Tresiba reached control similar to that on Lantus (insulin glargine 100 units/mL) and Levemir.1 Basaglar's type 1 trial compared it with another insulin glargine 100 units/mL product or a non-US insulin glargine, and several of its tables come from trials of that other product.2 Neither label names the other.
Severe low blood sugar was 10.4% to 12.7% of adults with type 1 diabetes in Tresiba trials, and 4% of adults with type 1 diabetes at 52 weeks on Basaglar.12 These numbers come from separate trials with different people, lengths and methods, so they are not a head-to-head comparison.
What else differs?
Both labels say their long action may delay recovery from a low, neither is used in an insulin pump or mixed with other insulins, and both list the usual insulin warnings: never sharing pens, low potassium and fluid retention with TZDs.12 Tresiba dose increases are 3 to 4 days apart, and children who need under 5 units a day use the vial.1
Which, if either, fits is for your prescriber. More detail: Tresiba side effects, Basaglar side effects, the Tresiba and Basaglar dosing schedules, the Tresiba and Basaglar missed-dose pages, the insulin degludec and insulin glargine guides, and Lantus vs Tresiba: how do the two long-acting insulins compare?.
Frequently asked questions
Has Tresiba been compared with Basaglar?
Does Tresiba have to be taken at the same time each day?
What if I miss a dose?
Can Dose Track remind me to take them?
Yes. You can log each basal dose in units and set a daily reminder.
Related comparisons
- Lantus vs Tresiba: how do the two long-acting insulins compare?Insulin glargine vs insulin degludec
- Basaglar vs Lantus: how do the two insulin glargine brands differ?Same insulin and dose, different pens and approved uses
- Toujeo vs Tresiba: how do glargine U-300 and degludec differ?Glargine U-300 vs degludec U-100 or U-200
- Free reconstitution calculatorVial strength and water to syringe units
See also
- Lantus side effects
- Lantus dosing schedule
- I missed my Lantus dose. What should I do?
- Soliqua vs Xultophy: how do the two insulin and GLP-1 pens differ?
- Toujeo vs Basaglar: how do the two insulin glargine pens differ?
Track it in Dose Track: GLP-1 tracker, TRT tracker or peptide tracker.
Sources
- Tresiba (insulin degludec) injection prescribing information and Patient Information, sections 1, 2, 3, 5, 6, 14 and 16. DailyMed, version of July 20, 2022.
- Basaglar (insulin glargine) injection 100 units/mL prescribing information and Patient Information, sections 1, 2, 3, 5, 6, 14 and 16. DailyMed, version of August 10, 2026.
All compound comparisons · All compound guides · Peptide tracking in Dose Track